この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。
規制と法律 · 2002/10/251 分で読めます
Bulk Aspirin from the People's Republic of China: Final Results of Changed Circumstances Review
ローカル自動翻訳 · 情報源の原言語
概要
On August 7, 2002, the Department of Commerce published a notice of preliminary results of its changed circumstances review in bulk aspirin from the People's Republic of China examining whether Jilin Henghe Pharmaceutical is the successor-in-interest to Jilin Pharmaceutical Company Ltd. and Jilin Pharmaceutical Import and Export Corporation. We have now completed the changed circumstances review and determine Jilin Henghe Pharmaceutical to be the successor-in-interest to Jilin Pharmaceutical Company Ltd. and Jilin Pharmaceutical Import and Export Corporation.
情報源の原言語: Federal Register — All Documents原文の発表を開く →